AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biowa who wrote (1674)	11/16/1999 2:13:00 PM
From: RWReeves	Read Replies (1) of 2173

The complications are the real long term cost that scares the H*** out of insurers. So as they've learned from DCCT even a little better control goes a long way. Improving control for type I's is already enough for me, Type II's have so many more options. Let's not overlook Novo's pretty sizable business built on type I's. I think HMO's will go a long way to buy-in improved economic outcomes through improved control, fewer side effects, and fewer long term complications. Glad to see this finally come through. RWR

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next